Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874497 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Terminated
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00874497 is a Phase 2 study that was terminated before completion, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 84 participants.
The verdict
NCT00874497, a Phase 2 study, was terminated before completion, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.
Interventions
- DRUG placebo
- DRUG tetomilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2009-03 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874497
The ClinicalTrials.gov registry entry for NCT00874497 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00874497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00874497 about?
NCT00874497 is a clinical study titled "Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema". Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.
What is the current status of trial NCT00874497?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2009-03. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00874497?
The interventions under investigation include: placebo (DRUG), tetomilast (DRUG).
Who is sponsoring clinical trial NCT00874497?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.